美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

HORIZON KINETICS MEDICAL ETF

35.29

+0.33190.95%

盤後：35.290.00000.00%16:10 EDT

成交量：227

成交額：8,052

市值：1,658.40萬

市盈率：- -

高：35.30

開：35.30

低：35.29

收：34.96

52周最高：37.90

52周最低：28.87

股本：46.99萬

流通股本：46.99萬

量比：0.09

換手率：0.05%

股息：0.41

股息率：1.16%

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

康哲藥業(00867)：創新藥高選擇性TYK2抑制劑CMS-D001 獲得系統性紅斑狼瘡適應症藥物臨床試驗批准通知書

恒瑞創新藥凝血因子XI單抗SHR-2004注射液用於擇期膝關節置換手術後成年患者靜脈血栓預防的上市申請獲受理

白雲山：超10個創新藥管線引進項目已完成立項

康泰醫學：獲得兩項醫療器械註冊證

ETF日報(09.14)丨WCLC臨床數據密集兑現，創新藥板塊震盪回升算力需求預期遭重估

強生骨科業務引阿波羅興趣，潛在200億美元交易推動盤前股價上漲1.2%

強生股價盤前上漲1.2%，此前有報道稱阿波羅全球管理公司有意收購強生旗下骨科業務，潛在交易估值約為200億美元。

ETF異動 | 華夏恒生生科(03069)升逾4% WCLC臨床數據催化密集機構看好創新藥投資機會

【券商聚焦】華創證券維持翰森製藥（03692）推薦評級指創新藥驅動業績增長

A股收評：創業板指震盪走低跌1.1%，培育鑽石、創新藥、MLCC概念板塊漲幅居前

樂高科技、艾迪爾等35家藥企涉商業賄賂，登上貴州醫保基金失信企業「黑榜」

創新藥闖關醫保

国际金融报

港股異動 | 創新藥概念股全線走高 WCLC臨床數據重磅催化機構指回調後配置價值凸顯

螞蟻集團入股醫療服務商風石健康

「超30家藥企長期行賄」，涉案醫院回應

A股午評：滬指低開高走漲0.16%，MLCC概念、創新藥、培育鑽石板塊表現活躍

醫療服務板塊走高，萬邦醫藥20cm漲停

強生Rybrevant聯合化療在EGFR外顯子20插入突變非小細胞肺癌中實現迄今報告最長的中位總生存期

強生：RYBREVANT聯合化療在EGFR外顯子20插入突變非小細胞肺癌中實現已報告的最長中位總生存期。

創新藥企赴港IPO提速小分子創新藥成主力賽道

经济参考报

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrcrest.com/hant/stock/MEDX/news?page=2"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"MEDX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MEDX\",,,,,undefined,":{"symbol":"MEDX","market":"US","secType":"STK","nameCN":"HORIZON KINETICS MEDICAL ETF","latestPrice":35.2891,"timestamp":1789416000000,"preClose":34.9572,"halted":0,"volume":227,"hourTrading":{"tag":"盘后","latestPrice":35.2891,"preClose":35.2891,"latestTime":"16:10 EDT","volume":7,"amount":247.0237,"timestamp":1789416603919,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.009494467520281871,"floatShares":469946,"shares":469946,"eps":0,"marketStatus":"盤後交易","change":0.3319,"latestTime":"09-14 19:52:33 EDT","open":35.3,"high":35.3,"low":35.2891,"amount":8052,"amplitude":0.000312,"askPrice":35.65,"askSize":1,"bidPrice":34,"bidSize":25,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"收盤","tradingStatus":0,"beginTime":1789430400000},"marketStatusCode":4,"adr":0,"exchange":"NASDAQ","adjPreClose":34.9572,"sharesOutstanding":569946,"nav":35.04,"aum":16466907.84,"dividendRate":0.01159,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":35.2891,"preClose":35.2891,"latestTime":"16:10 EDT","volume":7,"amount":247.0237,"timestamp":1789416603919,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.087916},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MEDX\",,,,,undefined,":{"symbol":"MEDX","floatShares":469946,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.087916,"shares":469946,"dividePrice":0.409,"high":35.3,"amplitude":0.000312,"preClose":34.9572,"low":35.2891,"week52Low":28.8652,"pbRate":"--","week52High":37.9,"institutionHeld":0,"latestPrice":35.2891,"committee":0.923077,"eps":0,"divideRate":0.01159,"volume":227,"delay":0,"ttmEps":0,"open":35.3,"prevYearClose":33.2024,"prevWeekClose":34.9572,"prevMonthClose":36.417,"prevQuarterClose":36.7138,"fiveDayClose":36.6906,"twentyDayClose":35.6938,"sixtyDayClose":34.2263},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MEDX\",params:#limit:5,,,undefined,":[{"date":"2025-12-23","symbol":"MEDX","amount":0.4088,"announcedDate":"2025-12-22","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-23","defaultRemindTime":1766500200000,"name":"HORIZON KINETICS MEDICAL ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-24","payableDate":"2025-12-23","currency":"USD","dateTimestamp":1766466000000,"payDate":"2025-12-24"},{"date":"2024-12-24","symbol":"MEDX","amount":0.502335,"announcedDate":"2024-12-23","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-24","defaultRemindTime":1735050600000,"name":"HORIZON KINETICS MEDICAL ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-26","payableDate":"2024-12-24","currency":"USD","dateTimestamp":1735016400000,"payDate":"2024-12-26"},{"date":"2023-12-27","symbol":"MEDX","amount":1.379798,"announcedDate":"2023-12-26","type":"dividend","market":"US","newRecordDate":"2023-12-28","defaultRemindTime":1703687400000,"name":"HORIZON KINETICS MEDICAL ETF","recordDate":"2023-12-29","payableDate":"2023-12-28","currency":"USD","dateTimestamp":1703653200000,"payDate":"2023-12-29"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MEDX\",market:\"US\",,,undefined,":[{"executeDate":"2023-12-27","recordDate":"2023-12-28","paymentDate":"2023-12-29","value":1.379798,"currency":"USD"},{"executeDate":"2024-12-24","recordDate":"2024-12-24","paymentDate":"2024-12-26","value":0.502335,"currency":"USD"},{"executeDate":"2025-12-23","recordDate":"2025-12-23","paymentDate":"2025-12-24","value":0.4088,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MEDX\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MEDX\",pageSize:20,pageCount:2,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2667657414","title":"康哲藥業(00867)：創新藥高選擇性TYK2抑制劑CMS-D001 獲得系統性紅斑狼瘡適應症藥物臨床試驗批准通知書","url":"https://stock-news.laohu8.com/highlight/detail?id=2667657414","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667657414?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 18:23","pubTimestamp":1789381419,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康哲药业 公布，于2026年9月11日，创新药CMS-D001片获得中国国家药品监督管理局签发的药物临床试验批准通知书，于2026年9月14日收到药物临床试验批准通知书。NMPA同意集团开展临床试验以评价CMS-D001治疗系统性红斑狼疮适应症的有效性和安全性。CMS-D001作为高选择性TYK2抑制剂，相较于泛JAK抑制剂，CMS-D001对其他JAK家族激酶的影响较小，可在长期疾病控制中维持疗效并降低相关安全风险。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495742.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LNGR","SG9999015986.USD","SG9999015978.USD","LU2488822045.USD","159992","SG9999015945.SGD","BK1574","IE00BYV24P56.USD","MDTX","SG9999004220.SGD","MEDX","IE00BMCWC346.EUR","IBBQ","BK1593","IBBJ","IE00BVYPNQ40.USD","IE00BVYPNP33.GBP","IE00BGHQDM52.EUR","PSYK","BK1161","SG9999015952.SGD","00867","SG9999004311.SGD","BMED","BK1191","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667657738","title":"恒瑞創新藥凝血因子XI單抗SHR-2004注射液用於擇期膝關節置換手術後成年患者靜脈血栓預防的上市申請獲受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2667657738","media":"恒瑞医药","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667657738?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 17:59","pubTimestamp":1789379940,"startTime":"0","endTime":"0","summary":"近日，恒瑞医药子公司北京盛迪医药有限公司收到国家药监局下发的《受理通知书》，公司1类创新药、凝血因子XI单克隆抗体SHR-2004注射液的药品上市许可申请获受理，拟定适应症为：用于择期膝关节置换手术的成年患者，以预防静脉血栓形成。该研究旨在评价行择期TKA的患者使用SHR-2004注射液预防静脉血栓栓塞症的有效性和安全性。此外，SHR-2004用于卵巢癌术后VTE预防的Ⅱ期试验已完成。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-09-14/doc-iniruxuy4531842.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IBBQ","BK1574","IPOS","MEDX","LNGR","BK1161","159992","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667654298","title":"白雲山：超10個創新藥管線引進項目已完成立項","url":"https://stock-news.laohu8.com/highlight/detail?id=2667654298","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667654298?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 17:36","pubTimestamp":1789378605,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["MEDX","IBBQ","LNGR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667659094","title":"康泰醫學：獲得兩項醫療器械註冊證","url":"https://stock-news.laohu8.com/highlight/detail?id=2667659094","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667659094?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 16:44","pubTimestamp":1789375491,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["HART","IEIH","MEDX","PTH","LNGR","GDOC","RSPH","LGHT","AGNG","MDEV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667582651","title":"ETF日報(09.14)丨WCLC臨床數據密集兑現，創新藥板塊震盪回升 算力需求預期遭重估","url":"https://stock-news.laohu8.com/highlight/detail?id=2667582651","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667582651?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 16:44","pubTimestamp":1789375451,"startTime":"0","endTime":"0","summary":"WCLC临床数据密集兑现，创新药板块震荡回升；AI巨头集体\"喊停\"，算力需求预期遭重估，通信板块多数走低。行业表现WCLC临床数据密集兑现，国内外投行相继看好中国CRO/CDMO复苏明确，创新药板块震荡回升。消息面上，9月12日至15日，2026年世界肺癌大会在韩国首尔举行，多项国产创新药临床数据集中亮相，中国新药入选口头报告19项、小型口头报告45项，双双刷新历史纪录，肺癌领域ADC与双抗数据成为焦点。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495613.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4550","AIQD","BK4585","BK4588","159992","FDN","MEDX","BK1161","AIVC","BK1574","LNGR","IBBQ","BAI","EPAI","06978","AIQU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171745492","title":"強生骨科業務引阿波羅興趣，潛在200億美元交易推動盤前股價上漲1.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=1171745492","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1171745492?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 16:18","pubTimestamp":1789373891,"startTime":"0","endTime":"0","summary":"据报道，强生公司的骨科业务部门吸引了阿波罗全球管理的关注，这一潜在交易估值或达200亿美元。受此消息提振，强生股价在盘前交易中上涨了1.2%。知情人士透露，私募股权巨头阿波罗已就收购强生骨科业务的可能性进行了初步接触。强生骨科业务涵盖创伤修复、关节置换、脊柱外科及运动医学等多个细分领域，在全球范围内拥有广泛的市场布局。截至发稿时，强生和阿波罗均未对此传闻发表官方评论。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4550","LU0889566641.SGD","SG9999002224.SGD","IE00BGHQF631.EUR","IE00BFTCPJ56.SGD","IE00BDGV0183.EUR","IE00B7SZLL34.SGD","LU0006061336.USD","IE00BLSP4452.SGD","BK4568","IE0001KFT4U8.USD","LU2430703095.HKD","SG9999002232.USD","LU1221951046.USD","IE00B4R5TH58.HKD","LU0203347892.USD","LU0545562505.USD","LU0072461881.USD","SG9999001176.SGD","IE000MB6IJN5.SGD","LU0345770308.USD","LU1430594728.SGD","LU2750360641.GBP","LU2487616109.SGD","IE00B3PB1722.GBP","LU2129689605.HKD","IHE","LU1228905540.USD","LU0053666078.USD","LU0289739699.SGD","IE0002141913.USD","LU1496350502.SGD","FTXH","LU0098860793.USD","LU1732800096.USD","LU1228905037.USD","LU2756315318.SGD","LU1043141123.HKD","LU1674673691.USD","LU2430703178.SGD","LU0057025933.USD","IE00B19Z3B42.SGD","IE00BN8TJ469.HKD","LU0162691827.USD","LU1074936037.SGD","LU0472753341.HKD","IE00BBT3K403.USD","IE00BJJMRZ35.SGD","LU2236285917.USD","LU0683600562.USD","LU1221951129.SGD","LU0820562030.AUD","LU1280957306.USD","LU2133065610.SGD","LU2592432038.USD","BK4592","LU1551013342.USD","LU0289739343.SGD","LU1032955483.USD","LU2023250330.USD","IXJ","LU0210528500.USD","LU1057294990.SGD","LU1674673428.USD","BK4581","BK4534","IE000SO60NU8.SGD","BK4504","IE000BZT7R73.USD","IE00B3T34201.USD","LU0114720955.EUR","LU1718418525.SGD","RXL","LU1043141396.HKD","LU1244550494.USD","LU2471134796.USD","IE00BVYPNW00.USD","LU2129689431.USD","IE000M9KFDE8.USD","LU0070217475.USD","LU1989771016.USD","LU2602419157.SGD","LU0689626769.HKD","SGXZ57979304.SGD","IE0009355771.USD","LU0882574055.USD","PRVT","LU0106831901.USD","LU1066051811.HKD","LU1585245621.USD","IE000F7OJYX1.SGD","IE00BZ1G4Q59.USD","APO","LU0466842654.USD","LU0426417589.USD","LU1323610961.USD","LU0234572021.USD","IE00B42XCP33.USD","LU2750360997.AUD","LU0792757196.USD","BK4532","LU1059921491.USD","JDOC","LU1032466523.USD","LU1929549753.HKD","LU1894683264.USD","LU2471134879.HKD","LU0320765646.SGD","LU0345769128.USD","LU0795875169.SGD","LU1791807156.HKD","LU1261432733.SGD","LU0069063385.USD","LU0289961442.SGD","IE00B3S45H60.SGD","BK4007","SG9999013999.USD","LU0820561909.HKD","LU0122379950.USD","LU1162221912.USD","IE00BLSP4239.USD","IE0034235303.USD","LU1935042991.SGD","LU0943347566.SGD","IE00B775SV38.USD","LU1244550221.USD","LU2756315664.SGD","BK4135","BK4588","IYH","LU0432979614.USD","IE00B2B36J28.USD","LU1066053197.SGD","LU0820561818.USD","IE00B1BXHZ80.USD","LU1914381329.SGD","IE000WAW04H5.SGD","VHT","BMED","LU1061106388.HKD","LBO","LU0787776722.HKD","LU1196500208.SGD","LU0345770993.USD","LU2471134952.CNY","IE00BVYPNV92.GBP","LU0058720904.USD","LU1291159041.SGD","LU1668664300.SGD","IE00BSNM7G36.USD","SGXZ80539844.SGD","LU0994945656.USD","IE00BFXG1179.USD","LU2347655156.SGD","LU1732799900.SGD","LU1267930813.SGD","AAUM","LU2896262040.SGD","LU0795875086.SGD","TRUH","LU2089984988.USD","LU2403377893.USD","LU0345769631.USD","IE00B19Z3581.USD","LU1244550577.SGD","GPZ","SG9999001176.USD","LU2430703251.USD","LU0210536198.USD","LU2213496289.HKD","LU2468319806.SGD","MEDX","LU1023059063.AUD","LU1778281490.HKD","LU2129689514.USD","LU1145028129.USD","FHLC","LU0426412945.USD","LU1551013425.SGD","LU2456880835.USD","LU1506573853.SGD","LU0124676726.USD","LU0964807845.USD","BK4184","LU2471134523.USD","LU0640476718.USD","SG9999001440.SGD","LU0234570918.USD","LU0912757837.SGD","LU0203345920.USD","LU2112291526.USD","BK4585","IE00BJT1NW94.SGD","LU1894683348.USD","LU0511384066.AUD","LU1121112475.USD","LU0689472784.USD","LU1066051225.USD","LU1983299246.USD","LU2417539215.USD","GDOC","BK4533","LU1629891620.HKD","XLV","LU2505996509.AUD","IE0000B7K699.USD","BK4559","PJP","LU0985320562.USD","IE0002270589.USD","LU2505996681.GBP","IE00BKVL7J92.USD","LU1066051498.USD","JNJ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667659843","title":"強生股價盤前上漲1.2%，此前有報道稱阿波羅全球管理公司有意收購強生旗下骨科業務，潛在交易估值約為200億美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2667659843","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667659843?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 16:18","pubTimestamp":1789373891,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["JNJ","LU1032466523.USD","BK4184","APO","IE00BN8TJ469.HKD","VHT","LU1221951046.USD","IE00BDGV0183.EUR","LU0289739343.SGD","LU0320765646.SGD","LU2430703251.USD","LU1585245621.USD","BK4585","IE0009355771.USD","LU0792757196.USD","GDOC","IE000BZT7R73.USD","PRVT","LU2023250330.USD","FTXH","AAUM","LU0345769128.USD","LU0426412945.USD","IXJ","MEDX","IE000WAW04H5.SGD","TRUH","LU1066053197.SGD","LU1244550221.USD","IHE","PJP","BMED","LU0889566641.SGD","LU1430594728.SGD","JDOC","LU0882574055.USD","LU1066051225.USD","LU2896262040.SGD","LU1267930813.SGD","IE00BKVL7J92.USD","IYH","IE00B42XCP33.USD","RXL","BK4559","GPZ","LU2592432038.USD","LBO","LU0070217475.USD","FHLC","XLV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667554366","title":"ETF異動 | 華夏恒生生科(03069)升逾4% WCLC臨床數據催化密集 機構看好創新藥投資機會","url":"https://stock-news.laohu8.com/highlight/detail?id=2667554366","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667554366?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 15:17","pubTimestamp":1789370250,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，华夏恒生生科涨超4%。截至发稿，涨4.01%，报15.58港元，成交额6924.78万港元。本次WCLC会议上，中国新药表现亮眼，入选口头报告研究19项，小型口头报告研究45项，刷新记录。国金证券称，创新药企业扭亏节点到来，全年临床数据催化密集，叠加已BD出海管线海外临床进展顺利，看好创新药板块投资机会。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495572.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4550","03069","IBBQ","BK1574","BK4585","06978","159992","MEDX","FDN","BK4588","BK1161","LNGR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667655868","title":"【券商聚焦】華創證券維持翰森製藥（03692）推薦評級 指創新藥驅動業績增長","url":"https://stock-news.laohu8.com/highlight/detail?id=2667655868","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667655868?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 15:01","pubTimestamp":1789369287,"startTime":"0","endTime":"0","summary":"金吾财讯 | 华创证券发布研报指，翰森制药 2026年上半年实现总营业收入83.04亿元人民币，创新药收入约70.92亿元，占总收入比例约85.4%创历史新高；净利润42.58亿元。研发管线方面，公司创新药临床试验超70项，候选创新药超40个。华创证券指，公司创新药收入驱动业绩稳健增长，BD出海持续推进，在研管线储备丰富，看好聚焦创新和国际化的战略布局。预计2026-2028年营收分别为165.12/185.22/209.34亿元人民币，同比增长9.9%/12.2%/13.0%；归母净利润为61.10/67.78/75.09亿元人民币。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250109/MjdmY2Y4OTEwODUyNTc5NjI3Mg==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MjdmY2Y4OTEwODUyNTc5NjI3Mg==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1991502","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["161027","KCE","06978","MEDX","03692","LNGR","159992","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667534816","title":"A股收評：創業板指震盪走低跌1.1%，培育鑽石、創新藥、MLCC概念板塊漲幅居前","url":"https://stock-news.laohu8.com/highlight/detail?id=2667534816","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667534816?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 15:01","pubTimestamp":1789369262,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LNGR","MLCC","MEDX","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667536746","title":"樂高科技、艾迪爾等35家藥企涉商業賄賂，登上貴州醫保基金失信企業「黑榜」","url":"https://stock-news.laohu8.com/highlight/detail?id=2667536746","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667536746?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 14:51","pubTimestamp":1789368717,"startTime":"0","endTime":"0","summary":"根据公告，对于配送企业，根据信用评价结果限制或中止配送企业在贵州省的配送资格1-5年；对于生产企业，除提醒告诫、提示风险外，限制或中止相关涉案产品或全部产品挂网、投标资格。据悉，贵州省医保基金运行服务中心给出了修复信用评级的方法。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1789368658648386760","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["MEDX","BK1574","RSPH","BK1583","LNGR","PTH","LGHT","AGNG","HART","09996","GDOC","BK1100","IEIH","MDEV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667653941","title":"創新藥闖關醫保","url":"https://stock-news.laohu8.com/highlight/detail?id=2667653941","media":"国际金融报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667653941?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 14:46","pubTimestamp":1789368365,"startTime":"0","endTime":"0","summary":"张力制图9月5日至8日，2026年国家基本医保药品目录现场谈判（下称“国谈”）竞价工作在北京开展，上百家国内外药企代表到场参与。本次共有124个目录外药品入围谈判竞价环节，肿瘤、罕见病、慢性病、儿童用药等社会关注度较高的创新药均在列，有望通过谈判纳入新版国家医保目录。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609143873368645.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609143873368645.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LNGR","BK1574","159992","IBBQ","06978","BK1161","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667608630","title":"港股異動 | 創新藥概念股全線走高 WCLC臨床數據重磅催化 機構指回調後配置價值凸顯","url":"https://stock-news.laohu8.com/highlight/detail?id=2667608630","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667608630?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 13:39","pubTimestamp":1789364389,"startTime":"0","endTime":"0","summary":"消息面上，9月12-15日，2026年世界肺癌大会召开，多项中国创新药临床数据集中亮相，康方生物依沃西单药OS数据、B7H3ADC等成为焦点。中泰证券指出，WCLC集中披露的多项肺癌领域临床进展，进一步验证了中国创新药的临床价值和全球竞争力，或可积极把握创新药回调后的配置机会。机构普遍认为，三季度部分企业新增订单进入收入确认期，基本面有望持续改善。当前医药板块估值27倍PE，低于历史均值，回调后配置价值凸显。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495523.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1589","BK1574","LU0634319403.HKD","LU2476274308.USD","LU2476274720.SGD","IBBQ","01530","LU2097828805.USD","LU0348735423.USD","06978","LU0348784397.USD","LU0417516571.SGD","LU2242644610.SGD","IE00B543WZ88.USD","LU0417516738.SGD","159992","01177","09926","LU2097828557.USD","VXUS","LU0244354667.USD","01801","LU0348767384.USD","BK1161","LU1831875114.USD","LU1961090484.USD","09969","BK1593","BK4588","LU1969619763.USD","LNGR","LU0455707207.USD","IE00BZ08YR35.GBP","LU2778985437.USD","LU1188198961.HKD","LU0607220059.USD","KCAI","LU0326950275.SGD","MEDX","HK0000165453.HKD","LU0348827113.USD","LU0348825331.USD","KURE","BK1191","LU0348766576.USD","LU0561508036.HKD","LU2097828714.EUR","LU2488822045.USD","BK1521","IE00BPRC5H50.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667637017","title":"螞蟻集團入股醫療服務商風石健康","url":"https://stock-news.laohu8.com/highlight/detail?id=2667637017","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667637017?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 13:30","pubTimestamp":1789363802,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667863208","title":"「超30家藥企長期行賄」，涉案醫院回應","url":"https://stock-news.laohu8.com/highlight/detail?id=2667863208","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667863208?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 11:36","pubTimestamp":1789356960,"startTime":"0","endTime":"0","summary":"澎湃新闻首席记者 李潇潇9月13日，国家医保局发布《医疗机构涉医药购销商业贿赂案》一文提到，仅2025年下半年，河北医科大学第二医院就涉及9件司法刑事判决。在国家医保局9月13日最新披露的信息中，有超过30家医药企业长期对河北医科大学第二医院工作人员行贿。具体到河北祥恩医疗器械贸易有限公司一家，该公司为向河北医科大学第二医院销售价格虚高的医疗耗材，累计向该医院工作人员行贿2064万元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/jjxw/2026-09-14/doc-iniruhxa7301443.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-09-14/doc-iniruhxa7301443.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LNGR","IEIH","BK1574","BK1100","MDEV","09996","GDOC","LGHT","PTH","BK1583","AGNG","RSPH","MEDX","HART"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667632818","title":"A股午評：滬指低開高走漲0.16%，MLCC概念、創新藥、培育鑽石板塊表現活躍","url":"https://stock-news.laohu8.com/highlight/detail?id=2667632818","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667632818?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 11:31","pubTimestamp":1789356669,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["MLCC","MEDX","LNGR","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667634858","title":"醫療服務板塊走高，萬邦醫藥20cm漲停","url":"https://stock-news.laohu8.com/highlight/detail?id=2667634858","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667634858?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 10:31","pubTimestamp":1789353086,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120093998","title":"強生Rybrevant聯合化療在EGFR外顯子20插入突變非小細胞肺癌中實現迄今報告最長的中位總生存期","url":"https://stock-news.laohu8.com/highlight/detail?id=1120093998","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1120093998?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 09:47","pubTimestamp":1789350464,"startTime":"0","endTime":"0","summary":"强生公司日前公布了一项重磅临床数据——其旗下药物Rybrevant与化疗联用，在携带EGFR外显子20插入突变的非小细胞肺癌患者中，取得了目前公开报告中最长的中位总生存期。EGFR外显子20插入突变，历来被视为治疗难点，可选方案有限且疗效欠佳。观察人士指出，这不仅能巩固Rybrevant在精准医疗版图中的地位，更可能重塑晚期非小细胞肺癌的一线治疗格局。强生能否借此在竞争激烈的肺癌药物市场中进一步扩大优势，值得持续跟踪。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0289739343.SGD","IE00BLSP4239.USD","LU0124676726.USD","LU1894683264.USD","LU2213496289.HKD","LU2896262040.SGD","LU2756315318.SGD","LU1506573853.SGD","IE00BFXG1179.USD","IE0001KFT4U8.USD","LU1674673428.USD","IE0002270589.USD","IE0002141913.USD","BK4007","LU1057294990.SGD","IE000BZT7R73.USD","LU1989771016.USD","IE000M9KFDE8.USD","LU0820561818.USD","LU1074936037.SGD","LU1267930813.SGD","LU2456880835.USD","LU2471134523.USD","RXL","IE00BFTCPJ56.SGD","LU2023250330.USD","SG9999001176.SGD","SG9999001176.USD","LU1145028129.USD","LU0098860793.USD","LU1023059063.AUD","LU1043141123.HKD","LU0053666078.USD","LU2430703251.USD","IE00B1BXHZ80.USD","GDOC","FTXH","LU0795875169.SGD","LU1244550577.SGD","LU1732800096.USD","BK4581","BK4534","IE00BVYPNW00.USD","LU0070217475.USD","LU1066051225.USD","LU0210528500.USD","LU2471134796.USD","MEDX","TRUH","LU0426417589.USD","LU0432979614.USD","LU0114720955.EUR","LU0964807845.USD","LU0511384066.AUD","LU1935042991.SGD","LU2505996681.GBP","LU1551013342.USD","LU2602419157.SGD","IE00B3T34201.USD","LU2750360641.GBP","LU1066051811.HKD","LU1228905540.USD","LU2487616109.SGD","LU1221951129.SGD","LU1228905037.USD","LU1291159041.SGD","LU0234572021.USD","IE00BN8TJ469.HKD","LU1496350502.SGD","IE00B19Z3581.USD","LU0289961442.SGD","LU0820562030.AUD","LU1778281490.HKD","LU1983299246.USD","LU0795875086.SGD","LU0345770308.USD","IHE","JDOC","IE000SO60NU8.SGD","LU1162221912.USD","LU2403377893.USD","BK4592","LU1585245621.USD","LU1121112475.USD","LU0426412945.USD","LU2129689605.HKD","LU1221951046.USD","LU1430594728.SGD","LU0203345920.USD","IE00B7SZLL34.SGD","LU2505996509.AUD","LU2129689514.USD","XLV","LU0994945656.USD","LU0162691827.USD","SG9999002232.USD","BK4550","LU0289739699.SGD","BK4559","LU1894683348.USD","IE0000B7K699.USD","LU2471134879.HKD","IE00B42XCP33.USD","LU0058720904.USD","LU1059921491.USD","LU0203347892.USD","IE00BVYPNV92.GBP","LU1043141396.HKD","BK4568","IE00BGHQF631.EUR","LU0234570918.USD","LU0683600562.USD","IE000WAW04H5.SGD","IE00B19Z3B42.SGD","IXJ","IE00BZ1G4Q59.USD","BK4504","LU0943347566.SGD","SGXZ80539844.SGD","LU2347655156.SGD","LU1061106388.HKD","LU0472753341.HKD","LU0057025933.USD","LU2236285917.USD","LU0820561909.HKD","VHT","LU0069063385.USD","LU0210536198.USD","LU0985320562.USD","LU1914381329.SGD","SG9999001440.SGD","LU2089984988.USD","BK4585","LU2750360997.AUD","IE0009355771.USD","IE00BJT1NW94.SGD","IE00B2B36J28.USD","IE00BKVL7J92.USD","LU0320765646.SGD","LU2133065610.SGD","IE00BDGV0183.EUR","LU1244550494.USD","IE00B3PB1722.GBP","IYH","BK4533","LU2430703095.HKD","LU1066053197.SGD","LU0072461881.USD","LU0122379950.USD","LU2129689431.USD","LU1244550221.USD","IE000MB6IJN5.SGD","LU1929549753.HKD","JNJ","LU1718418525.SGD","LU0889566641.SGD","LU1032955483.USD","LU1196500208.SGD","LU1280957306.USD","PJP","IE000F7OJYX1.SGD","LU0689472784.USD","SG9999002224.SGD","LU1674673691.USD","LU1261432733.SGD","BMED","LU2468319806.SGD","LU2756315664.SGD","LU0689626769.HKD","LU2471134952.CNY","SG9999013999.USD","LU1032466523.USD","IE00BSNM7G36.USD","LU0792757196.USD","LU0912757837.SGD","IE00BBT3K403.USD","LU1551013425.SGD","LU2112291526.USD","LU2417539215.USD","IE00B4R5TH58.HKD","IE00BLSP4452.SGD","LU0545562505.USD","FHLC","IE00BJJMRZ35.SGD","LU0640476718.USD","SGXZ57979304.SGD","LU0787776722.HKD","IE0034235303.USD","LU0345770993.USD","BK4532","LU0345769128.USD","LU0882574055.USD","LU2430703178.SGD","LU2592432038.USD","LU1732799900.SGD","LU0345769631.USD","BK4588","LU1066051498.USD","LU0466842654.USD","LU1629891620.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667631840","title":"強生：RYBREVANT聯合化療在EGFR外顯子20插入突變非小細胞肺癌中實現已報告的最長中位總生存期。","url":"https://stock-news.laohu8.com/highlight/detail?id=2667631840","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667631840?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 09:46","pubTimestamp":1789350398,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IE00BLSP4239.USD","LU1894683264.USD","IHE","JDOC","IE0001KFT4U8.USD","IE0002141913.USD","LU1280957306.USD","PJP","LU0820561909.HKD","VHT","LU1674673691.USD","LU0985320562.USD","LU2089984988.USD","BMED","LU2471134523.USD","RXL","IE00BFTCPJ56.SGD","LU1032466523.USD","LU1145028129.USD","LU0053666078.USD","GDOC","FTXH","XLV","FHLC","BK4550","LU2133065610.SGD","IE00BDGV0183.EUR","BK4559","LU1244550494.USD","IE0000B7K699.USD","IYH","BK4533","LU2430703095.HKD","MEDX","LU0426417589.USD","TRUH","LU2471134879.HKD","LU2592432038.USD","LU0072461881.USD","LU0122379950.USD","LU0511384066.AUD","IE00BVYPNV92.GBP","LU1935042991.SGD","BK4568","IE00B3T34201.USD","IE00BGHQF631.EUR","LU0683600562.USD","BK4588","JNJ","IXJ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667635798","title":"創新藥企赴港IPO提速 小分子創新藥成主力賽道","url":"https://stock-news.laohu8.com/highlight/detail?id=2667635798","media":"经济参考报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667635798?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 07:52","pubTimestamp":1789343542,"startTime":"0","endTime":"0","summary":"【创新药企赴港IPO提速 小分子创新药成主力赛道】8月下旬以来，征祥医药、益方生物、迪哲医药、贝达药业、维眸生物、诺令生物、普莱医药、信立泰等多家企业，密集向港交所递交上市申请，掀起新一轮本土创新药闯关港股18A板块的热潮。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"eastmoney_highlight","url":"http://finance.eastmoney.com/news/1354,202609143872918250.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/news/1354,202609143872918250.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"eastmoney_highlight","symbols":["BK4127","MEDX","BK1574","REDS","159992","IPOS","FRHC","06978","BK1161","IBBQ","KCE","LNGR"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":13,"pageCount":2,"totalSize":243,"code":"91000000","status":"200"}]}}